Romiplostim Treatment for Thrombocytopenia in Patients With Wiskott-Aldrich Syndrome.

Overview

The rationale for this retrospective study is to evaluate the efficacy and safety of thrombopoietin-receptor agonist (TPO-RA) romiplostim for reducing thrombocytopenia and bleeding tendency in pediatric participants with genetically confirmed Wiskott-Aldrich syndrome (WAS).

Full Title of Study: “Retrospective Chart Review of Children With Wiskott-Aldrich Syndrome Who Received Romiplostim in Treatment of Thrombocytopenia.”

Study Type

  • Study Type: Observational
  • Study Design
    • Time Perspective: Retrospective
  • Study Primary Completion Date: December 27, 2019

Detailed Description

Thrombocytopenia is a life-threatening symptom in WAS patients. Subjects with WAS are at increased risk of debilitating and or life-threatening bleedings due to low platelet numbers. Hematopoietic stem cell transplantation is an effective treatment of WAS and all its symptoms yet requires time for donor search and is not widely utilized in cases with mild WAS with isolated thrombocytopenia. TPO-RAs have been used in individual WAS patients, wherein publications describing large WAS cohorts treated with TPO-RAs are lacking. Based on the previous reports, WAS patients in our Center have been receiving treatment with TPO-RA romiplostim since 2012. The aim of the study is to retrospective analyze patients' data in order to asses treatment efficacy and safety of romiplostim in WAS thrombocytopenia. The study will collect and analyze information that is already in the patients' medical records. Information about clinical data (assessment of bleeding tendency with a modified World Health Organization (WHO) Bleeding Scale), laboratory values (such as clinical and biochemical analysis of blood) will be included. Evaluation of the efficacy therapy was based on the results of physical examination, including bleeding events at the time of diagnosis and after 6-month TPO-RA was initiated and platelet response. A complete response was defined as a platelet count >100 x 109/L in the absence of bleeding symptoms, partial – 30 x 109/L higher than the patient's pretreatment baseline count to 100 x 109/L. Non-response was defined as not achieving a platelet count of > 30 x 109/L from the baseline count.

Interventions

  • Drug: Romiplostim
    • romiplostim once weekly subcutaneously at an initial dose of 8-9 µg/kg per week for at least 1 month to 1 year.

Arms, Groups and Cohorts

  • treatment
    • romiplostim once weekly subcutaneously at an initial dose of 8-9 µg/kg per week for at least 1 month to 1 year.

Clinical Trial Outcome Measures

Primary Measures

  • The percentage of participants with overall platelet response (complete response + partial response)
    • Time Frame: 1 month (30 day +/- 14 days)
    • A complete response defined as a platelet count >100 x 109/L, partial – 30 x 109/L higher than the patient’s pretreatment baseline count to 100 x 109/L.

Secondary Measures

  • Percentage of patients with a platelet response
    • Time Frame: until discontinuation, from at least one month to one year
  • Number of participants with bleeding events and severity of bleeding
    • Time Frame: until discontinuation, from at least one month to one year
    • The incidence and severity of bleeding events evaluated with a modified World Health Organization (WHO) Bleeding Scale. (G1=Petechiae, epistaxis <30 min, G2=Mild blood loss, hematomas, epistaxis >30 min, melanotic stool G3=Gross blood loss, requiring blood transfusions, G4=Fatal bleeding).
  • Number of participants with adverse events
    • Time Frame: until discontinuation, from at least one month to one year

Participating in This Clinical Trial

Inclusion Criteria

  • Age under < 18 years – Subject/legal representative has signed written informed consent. ? – Subjects diagnosed with WAS based on genetic findings. – Subjects with thrombocytopenia (platelet count of less than 70 x 109/L). – Subjects with a history of bleeding. – Subjects received treatment with romiplostim 8-9 µg /kg for at least 30 days – Available records of the points of analysis Exclusion Criteria:

• Patients, who do not meet the inclusion criteria.

Gender Eligibility: All

Minimum Age: N/A

Maximum Age: 18 Years

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Federal Research Institute of Pediatric Hematology, Oncology and Immunology
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • Anna Shcherbina, MD, PhD, Principal Investigator, National Research Center for Pediatric Hematology , Moscow, Russian Federation

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.